Integrated Commercialization Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Integrated Commercialization Pharmaceutical Import Records from India — 4 Products, $2.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Integrated Commercialization — Pharmaceutical Importer Profile (2026) | 4 Products, $2.9M Trade | TransData Nexus

Integrated Commercialization

Pharmaceutical Importer · United States · Advanced Antibiotics Focus · $2.9M Total Trade · DGFT Verified

Integrated Commercialization is a pharmaceutical importer based in United States with a total trade value of $2.9M across 4 products in 3 therapeutic categories. Based on 58 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Integrated Commercialization sources from 6 verified Indian suppliers, with Gland Pharma Limited accounting for 83.2% of imports.

Integrated Commercialization — Import Portfolio & Supplier Network

Integrated Commercialization import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Integrated Commercialization?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gland Pharma Limited	$10.1M	228	83.2%
Piramal Pharma Limited	$916.4K	24	7.5%
Maiva Pharma Private Limited

What Formulations Does Integrated Commercialization Import?

Formulation	Value	Ships
Meropenem for injection USP 1g/vial, 30ML	$800.0K	16
Neostigmine methylsulfate injection	$572.9K	14
Cyanocobalamin injection USP 1000mcg/ML(1MG/ML) 1ML fill in a	$501.3K	11
Cyanocobalamin injection USP 1000mcg/ML(1MG/ML) 1ML fill in a	$493.0K	12
Metho carbamol injection 1000MG/10ML (100MG/ML)	$404.3K	9
Daptomycin for injection (lyophilized),500MG/vial, 15ML	$400.0K	8
Cyanocobalamin injection USP 1000mcg/ML	$350.0K	7
Glycopyrrolate injection USP 0.2MG/ML	$312.9K	8
Glycopyrrolate injection USP 0.2MG/ML	$301.7K	8
Ampicillin & sulbactam for injection	$300.0K	6
Meropenem for injection USP 1g/vial 30ML	$300.0K	6
Daptomycin for injection (lyophilized) 500MG/vial, 15ML	$300.0K	6
Daptomycin for injection lyophilized 500MG/vial,15ML	$300.0K	6
Daptomycin for injection (lyophilized) 350MG/vial 15 ML	$250.0K	5
Meropenem for injection USP 1g/vial, 30ML	$240.0K	10

Integrated Commercialization imports 100 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Meropenem	Advanced Antibiotics	$1.9M	39	0.9%	10
2	Vancomycin	Antibiotics	$450.0K	9	0.5%	14
3	Ampicillin	Antibiotics	$300.0K	6	0.2%	14
4	Voriconazole	Advanced Antifungals	$200.0K	4	0.6%	19

Integrated Commercialization imports 4 pharmaceutical products across 3 categories into United States totaling $2.9M.

Integrated Commercialization — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Integrated Commercialization is a U.S.-based pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from India. The company has engaged in 58 shipments from India, totaling an import value of $2.9 million USD. Their product portfolio encompasses four distinct formulations across three therapeutic categories, with a concentration in advanced antibiotics and antifungals. The top five imported products include Meropenem, Vancomycin, Ampicillin, and Voriconazole, collectively accounting for 100% of their imports. The primary suppliers are GLAND PHARMA LIMITED, PIRAMAL PHARMA LIMITED, and MAIVA PHARMA PRIVATE LIMITED, with GLAND PHARMA LIMITED being the most significant contributor.

2Distribution Network

Integrated Commercialization's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the United States. While specific warehouse locations are not publicly disclosed, the company likely operates multiple facilities to facilitate nationwide distribution. Their logistics capabilities are tailored to handle the complexities of pharmaceutical supply chains, ensuring timely and compliant delivery of imported medications.

3Industry Role

In the U.S. pharmaceutical supply chain, Integrated Commercialization functions as a pharmaceutical importer, focusing on sourcing finished pharmaceutical formulations from international manufacturers, particularly in India. By importing these products, they play a crucial role in enhancing the availability of essential medications within the U.S. market, thereby contributing to the diversification and resilience of the pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Integrated Commercialization

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Integrated Commercialization's sourcing strategy exhibits a high degree of concentration, with 100% of their imports comprising the top five products. This concentration indicates a strategic focus on specific high-demand medications, potentially leveraging favorable pricing or exclusive distribution agreements. However, such dependency on a limited product range may pose risks related to market fluctuations or supply disruptions. The consistent volume of shipments from primary suppliers suggests stable and ongoing relationships, which are essential for maintaining supply chain continuity.

2Supply Chain Resilience

The resilience of Integrated Commercialization's supply chain is closely tied to the stability and reliability of their Indian suppliers. The company's reliance on a select group of suppliers, particularly GLAND PHARMA LIMITED, indicates a strategic choice to maintain quality and consistency. However, this concentrated sourcing approach may expose the company to risks associated with geopolitical events, regulatory changes, or operational challenges within these supplier organizations. Diversifying the supplier base and incorporating additional formulations could enhance supply chain resilience and mitigate potential disruptions.

Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the legal framework governing the importation, distribution, and marketing of drugs within the U.S. Under this act, all imported drugs must meet FDA standards for quality, safety, and effectiveness. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating and approving drug products, including those imported from foreign manufacturers. Additionally, the FDA enforces regulations related to drug labeling, manufacturing practices, and post-market surveillance to ensure public health protection.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are stringent. Importers must ensure that all drugs comply with FDA regulations, including those pertaining to Good Manufacturing Practices (GMP). The FDA recognizes GMP certifications from various international standards, such as EU GMP, WHO GMP, and PIC/S, provided they meet FDA criteria. Importers are responsible for verifying that their foreign suppliers hold valid GMP certifications and that the products meet FDA standards. Additionally, importers must obtain a wholesale distribution authorization, which involves registration with the FDA and adherence to specific operational standards to ensure the safe and effective distribution of pharmaceutical products.

Integrated Commercialization — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Integrated Commercialization's focus on importing advanced antibiotics and antifungals aligns with the ongoing demand for these critical medications in the U.S. market. The therapeutic areas of advanced antibiotics and antifungals are essential for treating a range of serious infections, including those caused by multi-drug-resistant organisms. The market demand for these products is driven by factors such as the increasing prevalence of resistant infections, the need for effective treatments in hospital settings, and the expansion of outpatient care requiring potent antimicrobial therapies. By concentrating on these therapeutic areas, Integrated Commercialization positions itself to meet a significant and growing need within the healthcare system.

2Sourcing Profile

Integrated Commercialization's sourcing strategy is centered on acquiring generic drug formulations from India, focusing on finished pharmaceutical products rather than active pharmaceutical ingredients (APIs) or bulk drugs. This approach allows the company to leverage India's robust pharmaceutical manufacturing capabilities, which are recognized for producing high-quality generics that meet international standards. By importing finished formulations, Integrated Commercialization can offer a diverse range of products to the U.S. market, catering to various therapeutic needs while ensuring compliance with FDA regulations.

Market Positioning

Seller's Guide — How to Become a Supplier to Integrated Commercialization

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the U.S. market through partnerships with importers like Integrated Commercialization. The company's concentrated sourcing strategy indicates a preference for specific high-demand products, suggesting that suppliers offering these products may find a receptive partner in Integrated Commercialization. Gaps in the current sourcing include potential opportunities in emerging therapeutic areas or formulations that complement the existing product portfolio. Indian exporters can explore these opportunities by aligning their offerings with the importer's strategic focus and ensuring compliance with FDA regulations.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Integrated Commercialization and the U.S. market must adhere to FDA regulations, including obtaining appropriate GMP certifications recognized by the FDA. Products must meet FDA standards for quality, safety, and effectiveness, and labeling must comply with FDA requirements, including being in English. Exporters should also be prepared to provide Affirmation of Compliance codes and other necessary documentation to facilitate the import process. Ensuring compliance with these standards is essential for successful market entry and distribution in the United States.

Frequently Asked Questions — Integrated Commercialization

What products does Integrated Commercialization import from India?

Integrated Commercialization imports 4 pharmaceutical products across 3 categories. Top imports: Meropenem ($1.9M), Vancomycin ($450.0K), Ampicillin ($300.0K), Voriconazole ($200.0K).

Who supplies pharmaceuticals to Integrated Commercialization from India?

Integrated Commercialization sources from 6 verified Indian suppliers. The primary supplier is Gland Pharma Limited (83.2% of imports, $10.1M).

What is Integrated Commercialization's total pharmaceutical import value?

Integrated Commercialization's total pharmaceutical import value from India is $2.9M, based on 58 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Integrated Commercialization focus on?

Integrated Commercialization imports across 3 categories. The largest: Advanced Antibiotics (67.2%), Antibiotics (25.9%), Advanced Antifungals (6.9%).

Get Full Integrated Commercialization Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.